Mehta Analysis: From Generics To Biosimilars – When Will History Hurry Up And Repeat Itself?
Executive Summary
More than three decades ago, the Hatch-Waxman Act ushered in a new model of pharma industry renewal by opening the door to effective generic competition after drug patent expiry and encouraging originators to invest in innovation. Viren Mehta, founding partner of Mehta Partners LLC, would like to see similar gains from biosimilar adoption.
You may also be interested in...
FTC Competition Hearings: PhRMA, Former Rep. Waxman Advocate Focus On PBMs
FTC is assessing possible changes to competition and consumer protection enforcement law and policy, with a hearing on Innovation and IP Policy set for Oct. 23-24.
FDA Commissioner’s Rx For US Biosimilars Market: Reform Contracting Practices And Payment Models
In unveiling the agency’s Biosimilar Action Plan, FDA's Gottlieb continued his pattern of provocative remarks by criticizing brand company practices and payment models that impede biosimilar competition and could ultimately undermine innovation. He also called for more action by the Federal Trade Commission and downplayed the impact interchangeability could have on biosimilar uptake.
Mehta Analysis: The Promise Of 2021
Next year promises a wide range of opportunities for biopharma, triggered by an all-in commitment by every company with something to combat – COVID-19. Viren Mehta of Mehta Partners LLC discusses.